Triventi secures $92m to advance clinical development of antibody therapy
Pharmaceutical Technology
OCTOBER 26, 2023
The Series A funds will go towards the clinical development of TRIV-509, with plans for a proof-of-concept atopic dermatitis study.
Adcentrx raises funds to advance ADCs into clinical development
Pharmaceutical Technology
APRIL 26, 2023
Biotechnology company Adcentrx Therapeutics has raised $38m in Series A+ financing to advance its pipeline of new antibody-drug conjugate (ADC) therapeutics into clinical development. ADRX-070 is the company’s lead candidate and is anticipated to enter a first-in-human Phase I clinical trial in the second half of 2023.
Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Anti-RANKL Monoclonal Antibody by Jiangsu Pacific Meinuoke Bio-Pharmarceutical for Osteoporosis: Likelihood of Approval
Pharmaceutical Technology
JUNE 19, 2024
Anti-RANKL Monoclonal Antibody is under clinical development by Jiangsu Pacific Meinuoke Bio-Pharmarceutical and currently in Phase I for Osteoporosis.
Antibody 
100
100 
Nona Biosciences and ModeX Therapeutics partner for antibodies discovery
Pharmaceutical Technology
MAY 24, 2023
HBM’s wholly owned subsidiary Nona Biosciences has entered an agreement with OPKO Health’s ModeX Therapeutics for the discovery of antibodies. ModeX Therapeutics will gain access to the fully human Harbour Mice platforms of Nona Bioscience for integration into its MSTAR platform to expedite the monoclonal antibodies’ discovery.
Antibody 147
147 
Corbus and CSPC Megalith sign licence agreement for antibody drug conjugate
Pharmaceutical Technology
FEBRUARY 14, 2023
Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latter’s new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). We look forward to working with CSPC to advance clinical development of this asset and realise its full potential.”
Antibody 130
130 
How Can You Manage the Complexity of Early Phase Clinical Development?
XTalks
JUNE 4, 2024
Oren Cohen, MD, FIDSA CMO & President of Clinical Pharmacology Fortrea Fortrea is a provider of comprehensive Phase I through IV clinical trial management, clinical pharmacology, market access solutions and other enabling services.
Cancer Research UK and UCB advance oncology antibody candidates
Drug Discovery World
MARCH 10, 2023
Cancer Research UK and UCB have agreed a clinical development collaboration to advance two of UCB’s investigational oncology antibody candidates through clinical trials. If successful in clinical trials the investigational candidates may have the potential to offer cancer patients access to new targeted treatment options.
Antibody 98
98 
Syncromune and Eucure enter antibody licence deal
Pharmaceutical Technology
OCTOBER 19, 2022
Syncromune and Biocytogen Pharmaceuticals’ wholly owned subsidiary Eucure Biopharma have entered an exclusive global licence agreement for OX40 antibody YH002 and two other active ingredients. . Eucure will oversee the production and delivery of the drug, while Syncromune will handle the clinical development and marketing.
Antibody 130
130 
Upstream Bio raises funds to advance clinical development of UPB-101
Pharmaceutical Technology
JUNE 9, 2023
It is also preparing for a swift transition to Phase III development. A new recombinant fully human immunoglobulin G1 monoclonal antibody, UPB-101, is now being evaluated in a Phase 1b trial to treat asthma. It targets the human thymic stromal lymphopoietin receptor to inhibit signalling.
New inhaled SARS-CoV-2 antibody treatment set to enter clinical trials
BioPharma Reporter
DECEMBER 13, 2021
Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.
Antibody 143
143 
TORL scores $158m in Series B2 to advance ADC cancer therapies
Pharmaceutical Technology
APRIL 10, 2024
TORL plans to use the funds to advance the clinical development of its antibody-drug conjugate (ADC) pipeline.
Samsung Biologics to help Enzolytics advance clinical development of mAbs
BioPharma Reporter
OCTOBER 11, 2021
Samsung Biologics and Enzolytics have entered into a strategic CDMO partnership agreement targeting monoclonal antibody production.
Three trends in the antibody-drug conjugate (ADC) market
Drug Discovery World
JUNE 1, 2023
Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1.
Antibody 98
98 
Partners explore NK cell therapy and bispecific antibodies combination
Drug Discovery World
DECEMBER 8, 2023
ONK Therapeutics and NAYA Biosciences have agreed to develop a combination therapy of ONK’s optimally-engineered natural killer (NK) cell therapies and NAYA’s FLEX-NK bispecific antibodies. The post Partners explore NK cell therapy and bispecific antibodies combination appeared first on Drug Discovery World (DDW).
Antibody 52
52 
Humanised bispecific antibody for asthma enters Phase I trial
Drug Discovery World
MARCH 8, 2024
Biopharmaceutical company Innovent Biologics has launched the first-in-human (FIH) Phase I clinical trial of IBI3002, a novel bispecific antibody targeting Interleukin 4 receptor α (IL-4Rα) and thymic stromal lymphopoietin (TSLP). In vitro assays have shown superiority over the marketed monoclonal antibodies to respective target.
Antibody 52
52 
Genmab’s Silver Anniversary: Reflecting on 25 Years of Breakthroughs in Antibody Therapeutics
XTalks
MAY 9, 2024
Genmab, a trailblazer in the field of antibody therapeutics, celebrates this milestone by reflecting on its impressive journey from a small-scale startup to a global leader in cancer treatment and beyond. Since then, innovative science has been at Genmab’s core, as we harness the power of human antibodies to improve the lives of patients.
Antibody 52
52 
Memo Therapeutics AG to Receive CHF 10.5 Million from Swiss Federal Funding Programme to Clinically Develop SARS-CoV-2 Antibody Against COVID-19
BioTech 365
DECEMBER 13, 2021
Million from Swiss Federal Funding Programme to Clinically Develop SARS-CoV-2 Antibody Against COVID-19 Memo Therapeutics AG to Receive CHF 10.5 Million from Swiss Federal Funding Programme to Clinically Develop SARS-CoV-2 Antibody Against COVID-19 … Continue reading →
New class of antibody cancer drug shows promise
Drug Discovery World
JULY 26, 2023
A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. The drug, MOv18 IgE, was developed by researchers at King’s College London.
Antibody 52
52 
BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910
Pharma Times
JUNE 2, 2023
BI-1910 is now the second of the company's anti-tumour necrosis factor receptor 2 programmes to enter clinical development - News - PharmaTimes
Antibody 109
109 
CAEL-101: A Fibril-reactive Monoclonal Antibody (mAb) that is Currently in Phase 3 Clinical Development – Global Emerging Insight and Market Forecasts 2020-2030 – ResearchAndMarkets.com
BioTech 365
JANUARY 6, 2021
CAEL-101: A Fibril-reactive Monoclonal Antibody (mAb) that is Currently in Phase 3 Clinical Development – Global Emerging Insight and Market Forecasts 2020-2030 – ResearchAndMarkets.com CAEL-101: A Fibril-reactive Monoclonal Antibody (mAb) that is Currently in Phase 3 Clinical Development – Global … Continue reading → (..)
Boehringer takes alteplase to phase 3 for COVID, but drops antibody
pharmaphorum
JULY 27, 2021
Boehringer Ingelheim’s latecomer antibody therapy for COVID-19 has been side-lined, as the company focuses its attention on its thrombolytic drug alteplase, heading into a phase 3 programme later this year. The hope was that an inhaled antibody would reach higher levels in the lung, where it is most needed, than systemic antibodies.
Antibody 98
98 
First patient dosed in trial of antibody for kidney disease
Drug Discovery World
JULY 6, 2023
The first patient has been dosed in the clinical Phase I evaluation of the Sema3A monoclonal antibody, part of the Evotec-Bayer multi-target research collaboration in kidney diseases. Sema3A is upregulated in injured human kidneys and implicated in the development and progression of acute and chronic kidney diseases.
Antibody 52
52 
Research partners hope to develop novel antibody-drug conjugates
Drug Discovery World
JANUARY 3, 2023
Mersana Therapeutics and a subsidiary of Merck have entered a research collaboration to discover novel Immunosynthen antibody-drug conjugates (ADCs) directed against up to two targets. . The post Research partners hope to develop novel antibody-drug conjugates appeared first on Drug Discovery World (DDW).
Antibody 52
52 
A personal view on antibody drug development
Drug Discovery World
APRIL 14, 2023
Dr Schon is applying his broad expertise from lead discovery to manufacture in order to progress differentiated, safe and developable bi-specific therapeutic ADC candidates to clinical development. This is even more relevant for combination therapies or bispecific antibodies.
Antibody 52
52 
Exciting opportunity to potentially design new antibody therapy with Absci and AsraZeneca collaboration
Outsourcing Pharma
DECEMBER 4, 2023
An AI-designed antibody against an oncology target can now be delivered following a collaboration between Absci Corporation and AstraZeneca.
Antibody 78
78 
FDA Grants Priority Review to Novel Bispecific Antibody for Multiple Myeloma
Pharmaceutical Commerce
FEBRUARY 21, 2024
Regeneron Pharmaceuticals’ linvoseltamab is currently in clinical development to treat adult patients with relapsed/refractory multiple myeloma who experienced disease progression following prior administration of at least three therapies.
Antibody 59
59 
Future of Bispecific Antibody: Exploring the Rise in Approvals
Roots Analysis
OCTOBER 4, 2023
Bispecific antibodies are a type of antibody that can bind to two different targets at the same time. I, recently, worked on a market research report, titled Bispecific Antibodies Market , 2023-2035. During the research, I noticed a significant increase in the number of FDA approvals for bispecific antibodies in recent years.
Antibody 40
40 
Fusion Pharmaceuticals receives FDA IND approval for FPI-2068
Pharmaceutical Technology
APRIL 13, 2023
FPI-2068, which we believe will be the first TAT for two validated targets to enter the clinic, was designed to provide enhanced tumour specificity resulting from the co-expression of the two targets when compared to individual monoclonal antibodies against each of these targets.”
Evotec Starts Clinical Development of Chikungunya Antibody together with NIAID and Leading Academic Research Organisation
BioTech 365
JANUARY 28, 2021
FIRST DOSE OF EVT894, A MONOCLONAL ANTIBODY AGAINST CHIKUNGUNYA VIRUS ADMINISTERED TO A HEALTHY PARTICIPANT IN A PHASE I … Continue reading → DGAP-News: Evotec SE / Key word(s): Miscellaneous 28.01.2021 / 07:30 The issuer is solely responsible for the content of this announcement.
Antibody 40
40 
Mayo Clinic researchers develop new antibody test to diagnose MS
Scienmag
MARCH 24, 2022
Mayo Clinic researchers have validated a new antibody test to diagnose multiple sclerosis (MS), a potentially disabling disease of the brain and spinal cord. An antibody typically consists of two immunoglobulin heavy chains and […]. ROCHESTER, Minn. Nearly 1 million people in the U.S.
Pyxis Oncology signs agreement to buy Apexigen
Pharmaceutical Technology
MAY 25, 2023
Apexigen discovers and develops a new generation of antibody therapeutics to treat cancer, along with new immuno-oncology products to harness the immune system to combat and eradicate cancer.
Antibody 130
130 
China’s NMPA accepts IND for SinoMab BioScience’s SM17 to treat asthma
Pharmaceutical Technology
MAY 22, 2023
SM17 is a humanised IgG4-k monoclonal antibody that targets IL-17RB to treat asthma, idiopathic pulmonary fibrosis (IPF), atopic dermatitis (AD) and other immunological disorders. It can suppress Th2 immune responses by binding to IL-17RB on Type 2 innate lymphoid cells (ILC2s).
Immune Response 273
273 
Gilead pledges $1.76bn to MacroGenics for bispecific cancer antibody
pharmaphorum
OCTOBER 18, 2022
Gilead Sciences has made yet another rush into the oncology category, licensing a bispecific antibody from MacroGenics in development as a treatment for CD123-positive blood cancers, including acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Along with the signing fee, there is another $1.7
Antibody 52
52 
Ono Pharmaceutical enters research deal with Monash University
Pharmaceutical Technology
JANUARY 16, 2023
Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). We look forward to working with Ono Pharmaceutical to accelerate treatments across a variety of diseases.”.
Research 130
130 
Celltrion develops tailored neutralising antibody cocktail treatment with CT-P59 to tackle COVID-19 variant spread using its antibody development platform
Drug Discovery Today
FEBRUARY 16, 2021
Celltrion is on track developing a neutralising antibody cocktail with Regdanvimab (CT-P59) tailored to fight against the emerging new variants. Celltrion has constructed a COVID-19 antibody portfolio and clinical development platform to help combat the spread of the virus mutations
Antibody 45
45 
Numab raises $110m to develop cancer bispecific antibodies
pharmaphorum
MAY 20, 2021
Switzerland’s Numab has raised 100 million Swiss francs – around $110 million – in Series C financing to develop bispecific antibodies for cancer and inflammation, with Novo Noldings and HBM Partners co-leading the investor syndicate. The post Numab raises $110m to develop cancer bispecific antibodies appeared first on.
Antibody 52
52 
Novo Nordisk announces positive results for haemophilia A?antibody
Drug Discovery World
JULY 13, 2022
Novo Nordisk has announced positive interim results for its Mim8 antibody which is being as a treatment for haemophilia A. . The study is assessing the safety and clinical use of Mim8 in patients with haemophilia A. Zero bleeds were reported in the eight participants treated with the therapy once monthly. . Official comments .
Antibody 52
52 
Sanofi makes another pipeline deal, tapping Adagene for antibody tech
pharmaphorum
MARCH 2, 2022
billion tie-up with Chinese cancer immunotherapy biotech Adagene, focused on developing a new generation of safer antibody-based therapies. million upfront to kick off the collaboration, which will see Adagene’s SAFEbody technology applied to monoclonal and bispecific antibodies for a range of immuno-oncology applications.
Antibody 52
52 
Astellas and Sutro partner to develop immunostimulatory ADCs
Pharmaceutical Technology
JUNE 28, 2022
Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). An iADC merges an antibody with a small molecule compound that elicits immunogenic cell death, and an immune-activating molecule.
Development 264
264 
FibroGen and Fortis sign exclusive licence deal for mCRPC drug candidate
Pharmaceutical Technology
MAY 9, 2023
FibroGen has signed an exclusive licence agreement with Fortis Therapeutics for the FOR46 antibody-drug conjugate (ADC) that targets a new epitope on CD46, a protein-coding gene. FOR46 is a natural fit with our research and development capabilities and expertise.
Drugs 130
130 
IONTAS and FairJourney Biologics Discover SARS-CoV2 Neutralizing Antibodies with Picomolar Potency
BioTech 365
SEPTEMBER 28, 2020
Panel of 15 potent antibodies selected that are optimally suited to clinical development and manufacturing Monoclonal antibodies have the potential to both treat infected patients and provide protection to the “at risk” population during the pandemic Viral neutralization data independently … Continue reading →
Antibody 52
52 
Agreement facilitates highly differentiated ADC targeting Tissue Factor
Drug Discovery World
AUGUST 21, 2024
Adcendo and Multitude Therapeutics have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with the development code ADCE-T02.
Antibody 52
52 
Novavax Announces COVID-19 Vaccine Clinical Development Progress
The Pharma Data
NOVEMBER 30, 2020
NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein adjuvanted with Novavax’ patented saponin-based Matrix-M to enhance the immune response and stimulate high levels of neutralizing antibodies. and Australia.
STRO-002 by Sutro Biopharma for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 19, 2023
STRO-002 is under clinical development by Sutro Biopharma and currently in Phase I for Refractory Acute Myeloid Leukemia. It is a monoclonal antibody conjugate that acts by targeting f olate receptor alpha (FolR alpha). Sutro Biopharma owns a manufacturing facility in San Carlos, California.
Antibody 100
100 
Let's personalize your content